READING, Pa., June 2, 2022 /PRNewswire/ — PharmaForce International (PFI) recently released a competitive intelligence report comparing the business operations and marketing spend of leading oncology sales and marketing organizations in United States. To compete in a highly competitive environment, these leading companies are constantly changing their business approaches. The report covers all the key findings and major changes in the oncology market. A noteworthy finding, in particular, is the widespread shift to tumor-specific sales channel alignments.
To better serve key customers, several of the companies featured in the oncology study have recently realigned their sales packages to a tumor-centric model. This approach provides a more personalized experience for healthcare professionals in oncology and hematology (HCP), such as direct access to industry subject matter experts in the field. Additionally, it provides healthcare professionals with tumor-specific triage to other tumor-aligned industry personnel when needed. These include, but are not limited to, Clinical Nurse Educators, Opinion Leader Liaisons, Regional Marketing Managers, and Medical Science Liaisons.
Allison KeylorAssociate Director of US Business at PFI, says that “given the competitive nature of the pharmaceutical industry, more and more companies want to ensure that they compete on a more granular basis.”
“We have observed that more companies are mapping via tumor specificity to ensure that a specific indication is being properly promoted and the needs of specific oncologists are being met,” says Keylor.
Other key findings captured in the US Oncology Benchmarking Report include:
- HCP Call Panel Information
- Evolution of virtual and face-to-face HCP interaction
- Revisions to promotional programming
- Change in sales approaches
- Co-promotion information
- Adoption of biosimilars in oncology
- Reduced promotion of CAR-T products
- Turnover and remuneration of staff in oncology
In addition to United Statesthe Oncology benchmarking study is also conducted in the five major European countries – France, Germany, Italy, Spainand the UK. EU5 Oncology reports will be supplemented by July 2022.
For more information on the report mentioned above, please contact Joyce Wedemeyer at [email protected] or by phone at 610-370-2906.
PharmaForce International (PFI) is a competitive intelligence firm with over two decades of experience in the pharmaceutical and biotechnology industries. PFI has become the market leader in business operations benchmarking and competitive intelligence.